Neuronetics said it secured $30 million in a fourth round of funding led by New Leaf Venture Partners. President and CEO Bruce J. Shook said the company will use the money to commercialize its NeuroStar TMS Therapy -- a device that uses magnetic pulses to treat depression -- and broaden its sales and customer support groups, among others.

Related Summaries